Background and Objectives: In spite of advancement of newer catheter based technologies, recanalization of chronic total occlusion (CTO) is still challenging. The aim of this study is to evaluate the clinical outcomes according to stents after coronary angioplasty in CTO lesions treated with drug eluting stent (DES). Method: Total 336 patients with CTO which had more than 3 months duration and TIMI 0 distal flow shown by coronary angiography and underwent percutaneous coronary intervention (PCI) were enrolled. The patients who had successful procedure were treated with DES. Group 1 (n=116) was defined as patients who had sirolimus eluting stent (SES), Group 2 (n=88) for paclitaxel eluting stent (PES) and Group 3 (n=43) for zotarolimus eluting stent (ZES). Major adverse cardiac events (MACEs) including cardiac death, myocardial infarction (MI), target lesion revascularization (TLR), target vessel revascularization (TVR) were evaluated and compared. Results: All patients were attempted PCI and the procedure was successful in 247 patients (73.5 %). Mean follow up duration was 348짹113 days and clinical follow-up rate was 99% (333 of 336). Baseline characteristics among the groups were not significantly different. Total 4 MACEs (1.4%) were detected as 1 TLR and 1 death due to subacute stent thrombosis in Group 1, 1 TLR in Group 2, 1 TVR in Group 3 and there were not statistical significance among groups (p=0.873). Restenosis rate will be presented. Conclusion: DES is safe and effective in patients with CTO and there is no significant differences among DES during PCI for CTO although long-term data have to be needed.